|
Vol 51(2017) N 2 p. 237-250; DOI 10.1134/S0026893317020145  S.V. Kulemzin1, V.V. Kuznetsova1, M. Mamonkin2, A.V. Taranin1,3, A.A. Gorchakov1,3* CAR T-cell therapy: Balance of efficacy and safety 1Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090 Russia2Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital and Houston Methodist Hospital, Houston, USA 3Novosibirsk State University, Novosibirsk, 630090 Russia *gorchakov@mcb.nsc.ru Received - 2016-08-22; Accepted - 2016-10-12 Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform. chimeric antigen receptor, T-cells, cancer, adoptive immunotherapy |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
